Published in Gene Therapy Weekly, March 24th, 2005
For the year ended October 31, 2004, the company reported a net loss of $186,858 or $0.02/share on product revenue of $929. The 2004 net loss was a reduction of $75,420 from the net loss reported in 2003.
Also, the company's fiscal year 2004 report details the status of the initial commercialization of its Vitrocell product line and its current research regarding the development of new methods for the growth and development of human pancreatic beta islets (Islets of Langerhans) from human stem cells.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.